Impact of conduction disturbances on left ventricular mass regression and geometry change following transcatheter aortic valve replacement

Our study aimed to compare the difference of LV mass regression and remodeling in regard of conduction disturbances (CD) following transcatheter aortic valve replacement (TAVR). A prospective analysis of 152 consecutive TAVR patients was performed. 53 patients (34.9%) had CD following TAVR, including 30 (19.7%) permanent pacemaker implantation and 23 (15.2%) new left bundle branch block. In 123 patients with 1-year follow-up, significant improvement of LV ejection fraction (LVEF) (baseline vs 12-month: 65.1 ± 13.2 vs 68.7 ± 9.1, P = 0.017) and reduced LV end-systolic volume (LVESV) (39.8 ± 25.8 vs 34.3 ± 17.1, P = 0.011) was found in non-CD group (N = 85), but not in CD group (N = 38). Both groups had significant decrease in LV mass index (baseline vs 12-month: 148.6 ± 36.9 vs. 136.4 ± 34.7 in CD group, p = 0.023; 153.0 ± 50.5 vs. 125.6 ± 35.1 in non-CD group, p < 0.0001). In 46 patients with 3-year follow-up, only non-CD patients (N = 28) had statistically significant decrease in LV mass index (Baseline vs 36-month: 180.8 ± 58.8 vs 129.8 ± 39.1, p = 0.0001). Our study showed the improvement of LV systolic function, reduced LVESV and LV mass regression at 1 year could be observed in patients without CD after TAVR. Sustained LV mass regression within 3-year was found only in patients without CD.

www.nature.com/scientificreports/ Methods Patient population. 170 consecutive patients (77 male, mean age 81.5 ± 6.9 years) with severe symptomatic aortic stenosis (AS), with extreme or high surgical risks, underwent TAVR in National Taiwan University Hospital from September 2010 to November 2017. Of them, a total of 18 patients were excluded for the following reasons: peri-procedural death (n = 2), previous PM implantation (n = 7), missing data in electrocardiogram and echocardiogram (n = 4), lost follow-up within 1 year (n = 3), THV explant 6 months after TAVR due to infected endocarditis (n = 1), and TAVR for failed surgical prosthesis (n = 1). A total of 152 patients were finally included.
Ethical approval statement. All patients had sign informed consent at our clinic, and all the clinical information were collected according the protocol of Asian TAVR registry (NCT02308150) which was also proved by the local institutional review board of National Taiwan University Hospital. The evaluation and management of above patients were carried out in accordance with current guideline of valvular heart disease 18 .
TAVR procedure. The TAVR was performed by a heart team composed of interventional cardiologists, cardiac surgeons, echocardiographer, and anesthesiologist. The pre-TAVR evaluation included transthoracic echocardiography and computed tomography (CT). The area and perimeter of the aortic valve annulus were analyzed through CT scan for selection of optimal valve size. The patients were implanted with CoreValve/Evolute R (Medtronic, Minneapolis, Minnesota) (n = 110, 72.3%), Sapien XT (Edwards Lifesciences, Irvine LLC, California) (n = 31, 20.4%), Lotus (Boston Scientific, Marlborough, Massachusetts) (n = 10, 6.6%) or Portico (Abbott Vascular, St. Paul, MN, USA) (n = 1, 0.7%) respectively. The depth of implantation was assessed by the angiography with angle vertical to the alignment of valve prosthesis, and was determined by the distance between the bottom of metallic frame and lowest annulus. The definitions of low implantation are: 6 mm below annular plane in CoreValve/Evolute R 19 , and 4 mm in Sapien XT, Lotus, or Portico 20 .
Post-TAVR follow-up including electrocardiogram and echocardiography. Electrocardiographic records were obtained from all patients at baseline, immediately after the procedure, and daily until hospital discharge. The diagnosis of intraventricular conduction abnormalities was based on American Heart Association/ American College of Cardiology Foundation/Heart Rhythm Society recommendations for the standardization and interpretation of the electrocardiogram 21 . New-onset LBBB was defined as any new LBBB occurring during the hospitalization period after the TAVR procedure that persisted at hospital discharge. PM implantation was indicated if third-degree or advanced second-degree atrioventricular block was found at any anatomic level that was not expected to resolve after the intervention and for sinus node dysfunction with documented symptomatic bradycardia, in agreement with the American Heart Association/ American College of Cardiology Foundation/ Heart Rhythm Society guidelines for device-based therapy of cardiac rhythm abnormalities 19 . The indication of PM implantation in the presence of LBBB with PR prolongation (> 200 ms) not expected to normalize was at the discretion of the physician. The selection of a single-chamber or dual-chamber pacemaker was left to the implanter. The definition of new CD was either documentation of a new-onset LBBB or the new need of PM before discharge. Transthoracic echocardiography examinations were performed at baseline, at 1 and 6-month, and annually during follow-up. Echocardiographic parameters included LV end-systolic dimension (LVESd) and volume (LVESV), LV end-diastolic dimension (LVEDd) and volume (LVEDV), septal wall thickness at end diastole (SWTd) and posterior wall thickness at end diastole (PWTd), LV ejection fraction (LVEF), aortic valve area (AVA), trans-aortic valve peak and mean pressure gradient were measured. The LVEDV and LVEF were measured by the biplane Simpson's method from apical views. The AVA was estimated by the 2-dimensional Doppler method using the continuity equation. The LV mass was calculated by the formula as shown below: LV mass = 0.8 × {1.04 [(LVEDd + PWTd + SWTd) 3 − (LVEDd) 3 ]} + 0.6 g. The LV mass index (LVMi) was calculated by LV mass indexed to body surface area 22 .
Statistical analysis. Categorical data were presented as numbers (percentages) and compared using the Fisher's exact tests or Pearson's Chi-square test. Continuous variables were expressed as mean ± SD and were tested for normality using the Shapiro-Wilks test. The multivariate analysis were adjusted for baseline differences in the univariate analysis including variables with a value of P ≤ 0.20, such as gender, diabetes mellitus, previous myocardial infarction, LVEDd, valve type and low implantation, and using stepwise method. Comparisons between two groups were performed using independent Student's t tests and pairwise data were compared by the paired t test if data were normally distributed. Pairwise comparisons of non-normally distributed data were tested with Wilcoxon's signed-rank tests and analyzing of independent variables was realized by Mann-Whitney U test. Generalized estimated equations for repeated measurement were performed to evaluate temporal changes in LVMi before and after TAVR. The results were considered significant at values of P < 0.05. Data analyzed with STATA version 14.2.

Discussion
It was already known that new CD after TAVR had negative effect on LV function recovery [11][12][13][14][15] , and also had a trend toward a lower rate of LV reverse remodeling at 1-year follow-up 13 . Hoffmann et al. also reported that 1-year change in LVESV was significantly different between the patients with and without new CD 14 . Dimitriadis et al. 15 evaluated the impact of TAVR-related CD on myocardial performance with longer follow-up period (mean: 29.1 ± 16.9 months). They found that the changes both in LVESd and LVEDd were significantly different between these two groups. However, the impact of new CD on LV mass regression and remodeling, were less well described. The main findings of this study are: (1) clinical risk factors of new onset CD after TAVR are male sex and low THV implantation. (2) At 1-year, significant LV mass regression could be observed both in CD and non-CD group, but more pronounced in non-CD group. LVEF improvement as well as LVESd and LVESV reduction could only be found in the non-CD group. (3) At 3-year, sustained LV mass regression and a trend toward reduced LVEDV and LVESV could only be observed in the non-CD group. The results not only remind the operators to avoid low implantation during procedure, but also urge the device manufactures to make every effort to prevent new CD, especially as TAVR is now being extended to a younger and lower risk population.
Several clinical and experimental studies have established the potential adverse effects of long term LBBB and right ventricular (RV) pacing on LV function. Early activation of RV may lead to a decrease in cardiac  www.nature.com/scientificreports/ output as well as intraventricular and interventricular dyssynchrony, thus resulting in LV systolic dysfunction and remodeling 8,9,22,23 . In addition, the asynchronous ventricular activation leads to redistribution of circumferential shortening and myocardial blood flow, and then results in myocardial hypoperfusion in the absence of flow-limiting coronary artery disease [24][25][26] . The detrimental effects on LV geometry and function have been considered as one of possible mechanisms to explain why poorer functional status was observed in the population with post-TAVR LBBB, which has been illustrated in several studies 27 . The hypothesis is also congruent with observations that in chronic right ventricular pacing, heart failure hospitalization occurs more frequently in patients with depressed systolic function than in patients with normal systolic function 28 . Dobson et al. 29 using cardiac magnetic resonance, evaluated 24 patients with new LBBB following TAVR, matched with 24 patients with a narrow post-procedure QRS. Similar to our findings, significant improvement of LVEDV as well as reduced indexed LVESV at 6-months were seen only in narrow QRS group but not in the post-TAVR LBBB group. The authors concluded that TAVR-induced LBBB is associated with less favorable cardiac reverse remodeling at medium term follow up. However, these results were limited by its small case numbers and short follow-up period to provide longer term evidence of the adverse impact of new CD on cardiac reverse remodeling.
The difference of LV mass regression in long term follow-up between the patients with and without CD could be considered as a consequence of different geometric change after TAVR. In the first year after TAVR, the LV mass regression mostly resulted from the decrease of LV wall thickness in response to increased AVA and LV unloading, which could be demonstrated by our findings and previous study 30,31 . Interestingly though, the LV mass regression was more pronounced in non-CD group (CD vs non-CD group: 8% vs 18%) despite similar post-TAVR AVA in both groups. Less LV mass regression in CD group may result from the slight increase in LVEDd and LVEDV at 1 year, in contrast to the slight reduction of LVEDd and LVEDV in non-CD group. The effect of LV dimension and volume change to mass regression became more pronounced at 3-year follow-up. In non-CD group, sustained LV mass regression was observed along with sustained LVEDd and LVEDV reduction. The stationary (or slightly increasing) LVEDd and LVEDV in CD group, on the contrary, offset the wall thickness reduction and resulted in less LV mass regression. Our results may also provide explanation to the more pronounced LV mass regression observed in surgical aortic valve replacement compared with TAVR in prior randomized study 30 , as the incidence of CD was higher in TAVR group using self-expanding prosthesis.

Limitations
The main limitation of the present study was its small sample size, especially case numbers completing 3-year follow-up. Selection bias might exist, and it is mandatory to prove the hypothesis in a larger population. Second, the clinical significance of reverse LV remodeling following TAVR remains to be established. Third, the pacing percentage and the rate of pacemaker dependence among the patients receiving PM were not fully investigated. According to previous literature, overall pacemaker dependence after TAVR varied from 27 to 68% 32 , and of intrinsic atrioventricular conduction increased from 25.9% at 7 days to 59.3% at 30 days 19 . Future larger study with longer term follow-up on the clinical outcome and detailed analysis of the PM recordings is mandatory. Furthermore, the patients who died within the interval of 1 year to 3 years follow-up might have experienced less LV mass regression and poorer LVEF improvement. Thus, the potential of a competitive risk bias could not be excluded. www.nature.com/scientificreports/

Conclusions
We concluded that in patients with severe AS receiving TAVR, the improvement of LV systolic function associated with decrease of LVESV at 1 year could be observed in non-CD group. Significant LV mass regression could be found in both groups at 1 year, but more pronounced in non-CD group. In limited patients completing 3-year echocardiographic follow-up, sustained LV mass regression and a trend toward reduced LVEDV and LVESV were observed in patients without post-TAVR CD.